Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSC 100

Next Previous
Drug Profile

HSC 100

Alternative Names: CD34 selected VPA expanded umbilical cord blood cells - Tatcitus Therapeutics; HSC-100; Valproic Acid expanded cord blood stem cells - Tatcitus Therapeutics

Latest Information Update: 28 Mar 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tacitus Therapeutics
  • Developer Icahn School of Medicine at Mount Sinai
  • Class Gene therapies; Haematopoietic stem cells therapies; Immunotherapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Haematological malignancies

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for phase-I development in Haematological-malignancies(Adjunctive treatment) in USA (Parenteral, Infusion)
  • 21 Dec 2020 Tacitus Therapeutics and Icahn School of Medicine at Mount Sinai completes enrolment in a phase I trial in Haematological malignancies (Adjunctive treatment) in USA (Parenteral) (NCT03885947)
  • 10 Jan 2020 Tacitus Therapeutics and Mount Sinai Health System collaborate to develop stem cell therapies for haematological malignancies

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top